Inhibition of microRNA-155 Reduces Neuropathic Pain During Chemotherapeutic Bortezomib via Engagement of Neuroinflammation

Inhibition of microRNA-155 Reduces Neuropathic Pain During Chemotherapeutic Bortezomib via Engagement of Neuroinflammation

As a chemotherapeutic agent, bortezomib (BTZ) is used for the treatment of multiple myeloma with adverse effect of painful peripheral neuropathy. Our current study was to determine the inhibitory effects of blocking microRNA-155 (miR-155) signal on BTZ-induced neuropathic pain and the underlying mec...

Description complète

Détails bibliographiques
Auteurs principaux: Zongsheng Duan, Jian Zhang, Jing Li, Xiaochuan Pang, Hushan Wang
Format: Article
Langue:English
Publié: Frontiers Media S.A. 2020-03-01
Collection:Frontiers in Oncology
Sujets:
microRNA-155
bortezomib
chemotherapeutics
multiple myeloma
neuropathy
Accès en ligne:https://www.frontiersin.org/article/10.3389/fonc.2020.00416/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00416/full

Documents similaires